SOMATOSTATIN RECEPTOR POSITIVE
Clinical trials for SOMATOSTATIN RECEPTOR POSITIVE explained in plain language.
Never miss a new study
Get alerted when new SOMATOSTATIN RECEPTOR POSITIVE trials appear
Sign up with your email to follow new studies for SOMATOSTATIN RECEPTOR POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New radiation therapy targets Hard-to-Treat tumors in stomach and adrenal glands
Disease control Recruiting nowThis study tests a new drug that delivers radiation directly to cancer cells in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paraganglioma that have already been treated with radiation therapy. The drug works by attaching to a protein found on t…
Matched conditions: SOMATOSTATIN RECEPTOR POSITIVE
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:11 UTC
-
New hope for kids with Hard-to-Treat tumors: targeted radiation therapy trial opens
Disease control Recruiting nowThis study tests a radioactive drug called Lu-177 edotreotide in children aged 2 to 17 with tumors that have a specific marker (SSTR). The goal is to find the right dose and check if it is safe. About 20 children whose tumors came back or did not respond to prior treatment will t…
Matched conditions: SOMATOSTATIN RECEPTOR POSITIVE
Phase: PHASE1 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated May 26, 2026 07:27 UTC
-
New radiation therapy targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug that delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced lung, kidney, head and neck, digestive tract, or adrenal gland tumors that cannot be removed by surgery. The go…
Matched conditions: SOMATOSTATIN RECEPTOR POSITIVE
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC